Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Sep 21 - Sep 26
In this longer-term study patients who had responded to VYVANSE in the preceding 12-week open-label treatment phase were randomized to continuation of VYVANSE or placebo for up to 26 weeks of observation for relapse
Obesity: Identification, assessment and management
Heres how it may present: Neurological & Cognitive Brain fog Headaches or migraines Anxiety or panic attacks Insomnia Light or sound sensitivity Dizziness or balance problems Respiratory Shortness of breath Asthma-like symptoms Nasal congestion Frequent throat clearing Chronic cough Gastrointestinal Bloating Nausea or vomiting Diarrhea or constipation Acid reflux Abdominal pain Food intolerances Cardiovascular Heart palpitations Low blood pressure Flushing or facial redness Dizziness on standing (POTS) Musculoskeletal Joint pain Muscle aches Bone pain Dermatological Hives Itching without rash Rashes or eczema Dermatographia (skin writing) Systemic Temperature dysregulation Sensitivity to smells, chemicals, or stress Reactions to medications, supplements, or anesthesia Common Triggers of Mast Cell Degranulation People with MCAS often react to otherwise harmless stimuli
Older adults are more likely to be on multiple medications, increasing the potential for interactions
In most cases, eligibility can be determined after an initial consultation with a licensed provider
